Diagnostic and Prognostic Biomarkers in Dementia with Lewy Bodies: A UK Longitudinal Study.

The ENLIST-UK study is a 3-year longitudinal observational study aiming to recruit people with a diagnosis of dementia with Lewy bodies, Parkinson’s disease dementia or Alzheimer’s disease (for comparison purposes). Over the duration of the study, participants are invited to complete 5 visits (Screening, Baseline, Year 1, Year 2, Year 3). They are asked to complete neuropsychiatric questionnaires, undergo a blood test for biomarkers, and are also offered the option of a lumbar puncture to collect cerebrospinal fluid.

The main objective is to examine if the presence of  clinical core features, pro inflammatory cytokines or CSF AD markers are associated with increased rate of cognitive decline. A secondary objective is to build up a large cohort of people with dementia with Lewy bodies in the UK, collecting biological samples and longitudinal clinical and cognitive data.

This is a multicentered study within the United Kingdom of which Cambridge is a site. Kings College London  is the main sponsor.

To view the ENLIST-UK research summary click here. 

 

Sponsor: Kings College London

Funder: ARUK

People:
Chief Investigator – Professor Dag Aarsland
Principal Investigator – Professor John O’Brien
Local Study co-ordinator – Mrs Allison Bentley

For further information about this study please contact Allison Bentley
Email: Allison.bentley2@nhs.net 
Telephone: 01223 219531  /  Mobile: 07971014843